Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects - PubMed (original) (raw)
Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects
Luigi Sironi et al. Arterioscler Thromb Vasc Biol. 2005 Mar.
Abstract
Objective: Brain abnormalities, preceded by a systemic inflammation, develop in spontaneously hypertensive stroke-prone rats (SHRSP). In this model, we investigated whether the hydrophilic statin, rosuvastatin, influences the development of inflammation associated with brain abnormalities. Because differences in hydrophilicity/hydrophobicity contribute to the differences in statin pharmacology, we also evaluated the effects of simvastatin, a lipophilic molecule
Methods and results: SHRSP, fed a high-salt diet, were treated long-term with vehicle or rosuvastatin (1 and 10 mg/kg per day). Brain abnormalities developed after 40+/-5 days and after 60+/-5 days of salt loading, in vehicle-treated and in rosuvastatin-treated (1 mg/kg per day) SHRSP, respectively. After 100 days of treatment, no damage was detectable in 30% of the rats treated with the highest dose of the drug. In comparison with vehicle-treated SHRSP, rosuvastatin treatment attenuated the transcription of monocyte chemoattractant protein-1, transforming growth factor-beta1, IL-1beta, and tumor necrosis factor-alpha in the kidney, and of P-selectin in brain vessels and increased the transcription of endothelial nitric oxide synthase mRNA in the aorta. Urinary excretion of acute-phase proteins increased with time in vehicle-treated animals but remained negligible in drug-treated animals. These effects are independent of changes in physiological parameters. Treatment of SHRSP with simvastatin (2 to 20 mg/kg per day) did not exert any protective effect.
Conclusions: Rosuvastatin attenuates inflammatory processes associated with cerebrovascular disease.
Similar articles
- Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin.
Gelosa P, Ballerio R, Banfi C, Nobili E, Gianella A, Pignieri A, Brioschi M, Guerrini U, Castiglioni L, Blanc-Guillemaud V, Lerond L, Tremoli E, Sironi L. Gelosa P, et al. J Pharmacol Exp Ther. 2010 Jul;334(1):199-205. doi: 10.1124/jpet.110.165787. Epub 2010 Mar 23. J Pharmacol Exp Ther. 2010. PMID: 20332187 - Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E. Sironi L, et al. J Pharmacol Exp Ther. 2004 Dec;311(3):989-95. doi: 10.1124/jpet.104.072066. Epub 2004 Aug 9. J Pharmacol Exp Ther. 2004. PMID: 15302895 - Statin treatment and 3' polyadenylation of eNOS mRNA.
Kosmidou I, Moore JP, Weber M, Searles CD. Kosmidou I, et al. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2642-9. doi: 10.1161/ATVBAHA.107.154492. Epub 2007 Oct 4. Arterioscler Thromb Vasc Biol. 2007. PMID: 17916773 - Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Park JK, Mervaala EM, Muller DN, Menne J, Fiebeler A, Luft FC, Haller H. Park JK, et al. J Hypertens. 2009 Mar;27(3):599-605. doi: 10.1097/HJH.0b013e32831ef369. J Hypertens. 2009. PMID: 19262227 - Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders.
Mahalwar R, Khanna D. Mahalwar R, et al. Eur J Pharmacol. 2013 Jul 5;711(1-3):57-62. doi: 10.1016/j.ejphar.2013.04.025. Epub 2013 May 3. Eur J Pharmacol. 2013. PMID: 23648561 Review.
Cited by
- Rosuvastatin Enhances Alveolar Fluid Clearance in Lipopolysaccharide-Induced Acute Lung Injury by Activating the Expression of Sodium Channel and Na,K-ATPase via the PI3K/AKT/Nedd4-2 Pathway.
Xu HR, Yang Q, Xiang SY, Zhang PH, Ye Y, Chen Y, Xu KW, Ren XY, Mei HX, Shen CX, Ma HY, Smith FG, Jin SW, Wang Q. Xu HR, et al. J Inflamm Res. 2021 Apr 16;14:1537-1549. doi: 10.2147/JIR.S299267. eCollection 2021. J Inflamm Res. 2021. PMID: 33889010 Free PMC article. - Monocyte Transmodulation: The Next Novel Therapeutic Approach in Overcoming Ischemic Stroke?
Park J, Chang JY, Kim JY, Lee JE. Park J, et al. Front Neurol. 2020 Oct 22;11:578003. doi: 10.3389/fneur.2020.578003. eCollection 2020. Front Neurol. 2020. PMID: 33193029 Free PMC article. Review. - Cerebral Small Vessel Disease (CSVD) - Lessons From the Animal Models.
Mustapha M, Nassir CMNCM, Aminuddin N, Safri AA, Ghazali MM. Mustapha M, et al. Front Physiol. 2019 Oct 24;10:1317. doi: 10.3389/fphys.2019.01317. eCollection 2019. Front Physiol. 2019. PMID: 31708793 Free PMC article. Review. - The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.
Jabarpour M, Rashtchizadeh N, Argani H, Ghorbanihaghjo A, Ranjbarzadhag M, Sanajou D, Panah F, Alirezaei A. Jabarpour M, et al. Int Urol Nephrol. 2019 Dec;51(12):2235-2242. doi: 10.1007/s11255-019-02319-7. Epub 2019 Oct 22. Int Urol Nephrol. 2019. PMID: 31641998 Review. - Mitochondrial Dysfunction Contributes to Hypertensive Target Organ Damage: Lessons from an Animal Model of Human Disease.
Rubattu S, Stanzione R, Volpe M. Rubattu S, et al. Oxid Med Cell Longev. 2016;2016:1067801. doi: 10.1155/2016/1067801. Epub 2016 Aug 9. Oxid Med Cell Longev. 2016. PMID: 27594970 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials